In Cancer Clinical Trials, Federal and Industry Sponsors Play Complementary Roles

In cancer clinical trials, federal and industry sponsors play complementary roles

A comparative study of the cancer clinical trial portfolios supported by federal funding versus industry funding reveals they have distinct, interdependent roles in cancer research.The work, "Federal and Industry Sponsorship in US Cancer Clinical Trials," was published in JAMA Oncology.

Federal and industry sponsors play complementary roles in cancer clinical trials

A comparative study of the cancer clinical trial portfolios supported by federal funding versus industry funding reveals they have distinct, interdependent roles in cancer research.

Federal and Industry Sponsors Play Complementary Roles in Cancer Clinical

A new analysis of more than 11,000 cancer clinical trials in the United States has revealed a sharply divided but interdependent research system, in which federal agencies and pharmaceutical companies tend to pursue different questions at different stages of the drug-development process. The study, published online in JAMA Oncology, suggests that industry-sponsored research dominates the overall clinical-trial landscape, particularly in studies …

Federal and Industry Funding in U.S. Cancer Clinical Trials

A comparative analysis of 11,681 cancer clinical trials conducted in the United States has found a pronounced difference between the kinds of research supported by industry and the kinds backed by federal sponsors. Industry-sponsored trials were more likely to investigate single-agent drug therapies, while federally sponsored studies more often examined interventions that did not rely […]